📣 VC round data is live. Check it out!

Xvivo Perfusion Valuation Multiples

Discover Xvivo Perfusion's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Kuros Biosciences, Dynavox Group, LifeTech Scientific, SEEGENE and more.

Xvivo Perfusion Overview

About Xvivo Perfusion

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all of the majority organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.


Founded

1998

HQ

Sweden

Employees

158

Financials (LTM)

Revenue: $99M
EBITDA: $21M

EV

$918M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Xvivo Perfusion Financials

Xvivo Perfusion reported last 12-month revenue of $99M and EBITDA of $21M.

In the same LTM period, Xvivo Perfusion generated $72M in gross profit, $21M in EBITDA, and $7M in net income.

Revenue (LTM)


Xvivo Perfusion P&L

In the most recent fiscal year, Xvivo Perfusion reported revenue of $92M and EBITDA of $18M.

Xvivo Perfusion is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 20%, and net margin of 5%.

See analyst estimates for Xvivo Perfusion
LTMLast FY202320242025202620272028
Revenue$99M$92M$64M$88M$87M
Gross Profit$72M$64M$48M$66M$64M
Gross Margin73%70%74%75%74%
EBITDA$21M$18M$18M$31M$12M
EBITDA Margin21%20%29%35%14%
EBIT Margin12%11%1%11%11%
Net Profit$7M$4M$10M$19M$3M
Net Margin8%5%15%21%3%

Financial data powered by Morningstar, Inc.

Xvivo Perfusion Stock Performance

Xvivo Perfusion has current market cap of $938M, and enterprise value of $918M.

Market Cap Evolution


Xvivo Perfusion's stock price is $29.76.

Xvivo Perfusion share price decreased by 1.5% in the last 30 days, and by 2.4% in the last year.

Xvivo Perfusion has an EPS (earnings per share) of $0.13.

See more trading valuation data for Xvivo Perfusion
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$918M$938M-0.7%-1.5%18.9%-2.4%$0.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Xvivo Perfusion Valuation Multiples

Xvivo Perfusion trades at 9.3x EV/Revenue multiple, and 43.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Xvivo Perfusion

EV / Revenue (LTM)


Xvivo Perfusion Financial Valuation Multiples

As of June 4, 2026, Xvivo Perfusion has market cap of $938M and EV of $918M.

Xvivo Perfusion has a P/E ratio of 126.3x.

LTMLast FY202320242025202620272028
EV/Revenue9.3x10.0x14.3x10.4x10.5x
EV/EBITDA43.9x50.4x49.6x29.6x76.1x
EV/EBIT75.0x89.5xn/m95.5x92.7x
EV/Gross Profit12.7x14.2x19.2x13.9x14.2x
P/E126.3x223.1x95.0x50.7xn/m
EV/FCF(97.4x)(73.2x)(87.5x)(104.3x)(56.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Xvivo Perfusion Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Xvivo Perfusion Margins & Growth Rates

Xvivo Perfusion grew revenue by 17% and EBITDA by 35% in the last fiscal year.

In the most recent fiscal year, Xvivo Perfusion reported gross margin of 70%, EBITDA margin of 20%, and net margin of 5%.

See estimated margins and future growth rates for Xvivo Perfusion

Xvivo Perfusion Margins

Last FY202420252026202720282029
Gross Margin70%75%74%73%
EBITDA Margin20%35%14%23%
EBIT Margin11%11%11%14%
Net Margin5%21%3%11%
FCF Margin(14%)(10%)(19%)(5%)

Xvivo Perfusion Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth17%38%(1%)24%
Gross Profit Growth22%38%(3%)22%
EBITDA Growth35%68%(61%)103%
EBIT Growth46%1557%3%51%
Net Profit Growth182%88%(85%)338%
FCF Growth(59%)(16%)85%(68%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Xvivo Perfusion Operational KPIs

Xvivo Perfusion's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.

Xvivo Perfusion's Rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Xvivo Perfusion's Rule of X is 82% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Xvivo Perfusion
LTMLast FY202320242025202620272028
Rule of 4046%46%---
Bessemer Rule of X82%82%---
Revenue per Employee-$0.6M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue36%37%39%35%37%
G&A Expenses to Revenue10%10%13%12%10%
R&D Expenses to Revenue16%16%23%18%16%
Opex to Revenue-59%74%64%62%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Xvivo Perfusion Competitors

Xvivo Perfusion competitors include Kuros Biosciences, Dynavox Group, LifeTech Scientific, SEEGENE, QuidelOrtho, Anteris Technologies US, Artivion, ChemoMetec, MedicalSystem Technology and Barco.

Most Xvivo Perfusion public comparables operate across Medical Devices, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Kuros Biosciences5.0x5.4x57.6x46.4x
Dynavox Group3.7x3.6x16.2x15.1x
LifeTech Scientific3.7x-17.1x-
SEEGENE1.9x1.9x7.4x7.7x
QuidelOrtho1.3x1.3x6.1x6.0x
Anteris Technologies US327.4x141.9x(7.0x)(6.3x)
Artivion2.7x2.6x13.3x12.9x
ChemoMetec12.2x11.9x23.3x21.7x

This data is available for Pro users. Sign up to see all Xvivo Perfusion competitors and their valuation data.

Start Free Trial

Acquisitions by Xvivo Perfusion

Xvivo Perfusion has acquired 2 companies to date.

Last acquisition by Xvivo Perfusion was on August 1st 2022. Xvivo Perfusion acquired Avionord (machine and perfusion unit) for $13M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Xvivo Perfusion

Avionord (machine and perfusion unit)
StarTeams
Description
Avionord's machine and perfusion unit provides organ preservation services using normothermic perfusion technology for kidney and liver transplants. Based in Italy, the service extends graft viability beyond 24 hours and integrates with O.R. workflows. Avionord partners with transplant centers in Europe to increase utilization rates.
-
HQ CountryItalyUnited States
HQ City
Padua
-
Deal Date1 Aug 202228 Oct 2021
Valuation$13M$13M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Xvivo Perfusion acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Xvivo Perfusion

When was Xvivo Perfusion founded?Xvivo Perfusion was founded in 1998.
Where is Xvivo Perfusion headquartered?Xvivo Perfusion is headquartered in Sweden.
How many employees does Xvivo Perfusion have?As of today, Xvivo Perfusion has over 158 employees.
Who is the CEO of Xvivo Perfusion?Xvivo Perfusion's CEO is Christoffer Rosenblad.
Is Xvivo Perfusion publicly listed?Yes, Xvivo Perfusion is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Xvivo Perfusion?Xvivo Perfusion trades under XVIVO ticker.
When did Xvivo Perfusion go public?Xvivo Perfusion went public in 2012.
Who are competitors of Xvivo Perfusion?Xvivo Perfusion main competitors include Kuros Biosciences, Dynavox Group, LifeTech Scientific, SEEGENE, QuidelOrtho, Anteris Technologies US, Artivion, ChemoMetec, MedicalSystem Technology, Barco.
What is the current market cap of Xvivo Perfusion?Xvivo Perfusion's current market cap is $938M.
What is the current revenue of Xvivo Perfusion?Xvivo Perfusion's last 12 months revenue is $99M.
What is the current revenue growth of Xvivo Perfusion?Xvivo Perfusion revenue growth (NTM/LTM) is 24%.
What is the current EV/Revenue multiple of Xvivo Perfusion?Current revenue multiple of Xvivo Perfusion is 9.3x.
What is the current EBITDA of Xvivo Perfusion?Xvivo Perfusion's last 12 months EBITDA is $21M.
What is Xvivo Perfusion's EBITDA margin?Xvivo Perfusion's last 12 months EBITDA margin is 21%.
What is the current EV/EBITDA multiple of Xvivo Perfusion?Current EBITDA multiple of Xvivo Perfusion is 43.9x.
What is the current FCF of Xvivo Perfusion?Xvivo Perfusion's last 12 months FCF is ($9M).
What is Xvivo Perfusion's FCF margin?Xvivo Perfusion's last 12 months FCF margin is (10%).
What is the current EV/FCF multiple of Xvivo Perfusion?Current FCF multiple of Xvivo Perfusion is (97.4x).
How many companies Xvivo Perfusion has acquired to date?As of June 2026, Xvivo Perfusion has acquired 2 companies.
What was the largest acquisition by Xvivo Perfusion?$13M acquisition of Avionord (machine and perfusion unit) on 1st August 2022 was the largest M&A Xvivo Perfusion has done to date.
What companies Xvivo Perfusion acquired?Xvivo Perfusion acquired Avionord (machine and perfusion unit) and StarTeams.
In how many companies Xvivo Perfusion has invested to date?Xvivo Perfusion hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Xvivo Perfusion

Lists including Xvivo Perfusion

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial